Mustang Bio
MBIO
55 hedge funds and large institutions have $35.8M invested in Mustang Bio in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
56% more call options, than puts
Call options by funds: $306K | Put options by funds: $196K
1% more capital invested
Capital invested by funds: $35.3M → $35.8M (+$487K)
0% more funds holding
Funds holding: 55 → 55 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$769K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$556K |
| 3 |
BlackRock
New York
|
+$481K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$215K |
| 5 |
Renaissance Technologies
New York
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10.3M |
| 2 |
6CM
683 Capital Management
New York
|
-$504K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$492K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$254K |
| 5 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$163K |
MBIO Hedge Fund Activity: Q4 2019 in Review
55 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Mustang Bio (MBIO) for Q4 2019, worth a combined $35.8M — up 1.4% from $35.3M a quarter earlier.
Fund positioning in MBIO was balanced in Q4 2019: 7 funds opened new positions, 7 closed out, 22 added to existing stakes and 11 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $769K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10.3M sold.
- 55 institutional investors held Mustang Bio (MBIO) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $35.8M of Mustang Bio stock for Q4 2019, up 1.4% quarter-over-quarter.
- 7 funds opened new Mustang Bio positions in Q4 2019 and 7 closed out, a net change of 0 holders.
- The largest Mustang Bio buyer in Q4 2019 was OrbiMed, an estimated $769K added.
- The largest Mustang Bio seller in Q4 2019 was Consonance Capital Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2019.